Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2018 Q2- Text added to 2018 Q3
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. sophomore Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
New words:
Anderson, AstraZeneca, begun, CCA, Center, children, chronic, CLL, demonstrated, demonstrating, differentiated, durably, duration, enrollment, esophageal, high, inhibition, investigation, investigational, Lineage, LLC, lymphocytic, main, MD, member, Mixed, mutant, myelodysplastic, olaparib, PLK, potent, previously, primary, promulgated, ready, rearrangement, recasting, retained, Rule, show, step, thenine, University, uterine, Wainwright, xenograft
Removed:
Food, liquid, ongoing, progressing, remained, trastuzumab
Valuein 2018 Q2 filing- Value in 2018 Q3 filing
Original filings
Filing view